These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 12740810

  • 1. Indolocarbazole glycosides in inactive conformations.
    Facompré M, Carrasco C, Vezin H, Chisholm JD, Yoburn JC, Van Vranken DL, Bailly C.
    Chembiochem; 2003 May 09; 4(5):386-95. PubMed ID: 12740810
    [Abstract] [Full Text] [Related]

  • 2. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
    Bailly C, Qu X, Chaires JB, Colson P, Houssier C, Ohkubo M, Nishimura S, Yoshinari T.
    J Med Chem; 1999 Jul 29; 42(15):2927-35. PubMed ID: 10425102
    [Abstract] [Full Text] [Related]

  • 3. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
    Anizon F, Belin L, Moreau P, Sancelme M, Voldoire A, Prudhomme M, Ollier M, Sevère D, Riou JF, Bailly C, Fabbro D, Meyer T.
    J Med Chem; 1997 Oct 10; 40(21):3456-65. PubMed ID: 9341921
    [Abstract] [Full Text] [Related]

  • 4. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
    Bailly C, Riou JF, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M.
    Biochemistry; 1997 Apr 01; 36(13):3917-29. PubMed ID: 9092822
    [Abstract] [Full Text] [Related]

  • 5. DNA binding properties of the indolocarbazole antitumor drug NB-506.
    Carrasco C, Vezin H, Wilson WD, Ren J, Chaires JB, Bailly C.
    Anticancer Drug Des; 2001 Apr 01; 16(2-3):99-107. PubMed ID: 11962518
    [Abstract] [Full Text] [Related]

  • 6. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
    Moreau P, Anizon F, Sancelme M, Prudhomme M, Bailly C, Carrasco C, Ollier M, Sevère D, Riou JF, Fabbro D, Meyer T, Aubertin AM.
    J Med Chem; 1998 May 07; 41(10):1631-40. PubMed ID: 9572888
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Synthesis, mode of action, and biological activities of rebeccamycin bromo derivatives.
    Moreau P, Anizon F, Sancelme M, Prudhomme M, Sevère D, Riou JF, Goossens JF, Hénichart JP, Bailly C, Labourier E, Tazzi J, Fabbro D, Meyer T, Aubertin AM.
    J Med Chem; 1999 May 20; 42(10):1816-22. PubMed ID: 10346933
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Syntheses and antiproliferative activities of 7-azarebeccamycin analogues bearing one 7-azaindole moiety.
    Marminon C, Pierré A, Pfeiffer B, Pérez V, Léonce S, Joubert A, Bailly C, Renard P, Hickman J, Prudhomme M.
    J Med Chem; 2003 Feb 13; 46(4):609-22. PubMed ID: 12570382
    [Abstract] [Full Text] [Related]

  • 12. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents.
    Bailly C, Dassonneville L, Colson P, Houssier C, Fukasawa K, Nishimura S, Yoshinari T.
    Cancer Res; 1999 Jun 15; 59(12):2853-60. PubMed ID: 10383146
    [Abstract] [Full Text] [Related]

  • 13. Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent.
    Moreau P, Anizon F, Sancelme M, Prudhomme M, Bailly C, Sevère D, Riou JF, Fabbro D, Meyer T, Aubertin AM.
    J Med Chem; 1999 Feb 25; 42(4):584-92. PubMed ID: 10052965
    [Abstract] [Full Text] [Related]

  • 14. Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition.
    Bailly C, Qu X, Graves DE, Prudhomme M, Chaires JB.
    Chem Biol; 1999 May 25; 6(5):277-86. PubMed ID: 10322124
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Novel 3',6'-anhydro and N12,N13-bridged glycosylated fluoroindolo[2,3-a]carbazoles as topoisomerase I inhibitors. Fluorine as a leaving group from sp3 carbon.
    Saulnier MG, Langley DR, Frennesson DB, Long BH, Huang S, Gao Q, Wu D, Fairchild CR, Ruediger E, Zimmermann K, St Laurent DR, Balasubramanian BN, Vyas DM.
    Org Lett; 2005 Mar 31; 7(7):1271-4. PubMed ID: 15787484
    [Abstract] [Full Text] [Related]

  • 18. Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono- and bisfuronaphthalimides.
    Bailly C, Carrasco C, Joubert A, Bal C, Wattez N, Hildebrand MP, Lansiaux A, Colson P, Houssier C, Cacho M, Ramos A, Braña MF.
    Biochemistry; 2003 Apr 15; 42(14):4136-50. PubMed ID: 12680768
    [Abstract] [Full Text] [Related]

  • 19. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
    Yoshinari T, Ohkubo M, Fukasawa K, Egashira S, Hara Y, Matsumoto M, Nakai K, Arakawa H, Morishima H, Nishimura S.
    Cancer Res; 1999 Sep 01; 59(17):4271-5. PubMed ID: 10485471
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.